HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, today announced that highly recognized cardiologist and researcher Douglas L. Mann, M.D. is joining as Chairperson of the company’s Clinical Advisory Board. Dr. Mann is a professor in the John T. Milliken Department of Medicine at the Washington University School of Medicine in St. Louis. (Photo: Business Wire)
HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards
HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Brian C. Thomas, Ph.D., has joined HAYA as Chairperson of the Board of Directors. Dr. Thomas, CEO and Founder of Metagenomi, brings extensive experience in biotech research and development. (Photo: Business Wire)